IDEAYA Biosciences, Inc. (IDYA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.2x

Market Cap

$3.82B

MomentumView details →

1D Return

−0.88%

YTD Return

+14.56%

RSI (14)

55.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.2x

Market Cap

$3.82B

RSI (14)

55.9

MomentumView details →

1D Return

−0.88%

YTD Return

+14.56%

SummaryUpdated Jun 1, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company founded in 2015 and headquartered in South San Francisco, California. The company went public in May 2019 and focuses on developing targeted cancer therapeutics using a synthetic lethality approach. IDEAYA identifies specific genetic vulnerabilities in cancer cells and develops drugs that exploit these weaknesses while sparing healthy cells. The company currently has multiple drug candidates in clinical trials and maintains strategic partnerships with major pharmaceutical companies including Pfizer and GlaxoSmithKline.

Ask drillr about IDEAYA Biosciences, Inc. →

ProfitabilityView details →

Gross Margin

−13.32%

Net Margin

−74.75%

EBITDA Margin

−90.75%

ROE (TTM)

−14.60%

ROA (TTM)

−13.36%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

+3244.67%

EPS YoY

+49.34%

FCF YoY

+36.08%

Revenue CAGR 3Y

+62.54%

EPS CAGR 3Y

+61.90%

EBITDA YoY

+37.20%

EarningsView details →

EPS (Actual)

−$1.22

EPS Surprise

−15.09%

Beats (12Q)

3/12

Next Q EPS Est

−$1.18

Avg Surprise (4Q)

−33.12%

Rev Surprise

10.44%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

10.45x

Quick Ratio

10.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

234.13M

Net Income (TTM)

−175.02M

Op. CF (TTM)

−186.83M

Next earningsNov 9, 2026 →

Latest newsMore news →

IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.16d ago

IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.31d ago

Similar companies

Adaptive Biotechnologies CorporationADPT Tango Therapeutics, Inc.TNGX Amylyx Pharmaceuticals, Inc.AMLX Catalyst Pharmaceuticals, Inc.CPRX Shanghai Haohai Biological Technology Co., Ltd.06826.HK Arcus Biosciences, Inc.RCUS Find similar companies →

Latest newsMore news →

IDEAYA Biosciences entered into a clinical collaboration with Genentech to evaluate IDE892 in combination with RG6620 in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma, with Genentech sponsoring the trial and joint governance overseeing the study.16d ago IDEAYA Biosciences reported financial results for the second quarter ended June 30, 2026, with cash and marketable securities of approximately $1.24 billion as of that date.31d ago